pharma · Phenylketonuria · Achondroplasia
BioMarin Pharmaceutical Australia Pty Ltd
BioMarin Pharmaceutical Australia is a pharma organization headquartered in San Rafael, USA. Primary therapeutic focus areas include Phenylketonuria, Achondroplasia, Duchenne Muscular Dystrophy, Phenylketonuria (PKU), Hy
Phase 3 · small molecule · Hypochondroplasia
Voxzogo (vosoritide) is a subcutaneous injection developed by BioMarin Pharmaceutical Australia for the treatment of hypochondroplasia, a genetic skeletal dysplasia characterized by short stature and disproportionate limb growth. The drug is a small-molecule therapeutic targeting the musculo-skeletal system. Voxzogo ha
Internal code 111-303
Voxzogo (vosoritide) is a subcutaneous injection developed by BioMarin Pharmaceutical Australia for the treatment of hypochondroplasia, a genetic skeletal dysplasia characterized by short stature and disproportionate limb growth. The drug is a small-molecule therapeutic targeting the musculo-skeletal system. Voxzogo has achieved regulatory approval in multiple jurisdictions: approved in Australia (May 2023), the European Union (November 2025), and the United States. The program is currently in Phase 3 clinical development, with an active randomized, double-blind, placebo-controlled multicenter study evaluating efficacy and safety in children with hypochondroplasia. BioMarin's strategy centers on establishing Voxzogo as a disease-modifying therapy for a rare genetic condition with limited treatment options. The drug is administered as a powder and solvent for solution for injection, available in 0.56 mg and 1.2 mg formulations in Australia. Regulatory approvals across major markets represent significant clinical and commercial validation, though specific efficacy endpoints and comparative clinical data are not disclosed in available sources.
Hypochondroplasia is a rare genetic skeletal dysplasia with limited therapeutic options, representing a significant unmet medical need in pediatric rare disease. The condition results in growth deficiency and skeletal abnormalities, with substantial impact on patient quality of life and long-term health outcomes. Voxzogo addresses this unmet need by offering a disease-modifying approach to a condition previously managed primarily through supportive care. The approval across Australia, the EU, and the US demonstrates regulatory confidence in the therapeutic approach and establishes market access in key developed markets. The competitive landscape includes various musculo-skeletal therapies (bisphosphonates, monoclonal antibodies, bone morphogenetic proteins), though most are not specifically indicated for hypochondroplasia. Voxzogo's approval status and ongoing Phase 3 development position it as a differentiated therapy in the rare skeletal dysplasia space. Commercial significance is tied to the rare disease population size, pricing strategies in orphan indications, and potential label expansions. The pediatric focus and subcutaneous administration route align with practical clinical needs in managing rare genetic conditions in children.
Drug Class: Musculo-skeletal system therapeutic (ATC M05)
Modality: Small molecule
Route of Administration: Subcutaneous injection
Formulations: Powder and solvent for solution for injection; available strengths include 0.56 mg and 1.2 mg (Australia); 1.2 mg formulation also noted
Mechanism of Action: Not disclosed in available regulatory or clinical documentation
Target: Not disclosed in available regulatory or clinical documentation
Related Therapies: Competitive musculo-skeletal agents include bisphosphonates (ibandronic acid, alendronic acid combinations), monoclonal antibodies (denosumab), bone morphogenetic proteins (INDUCTOS), and other skeletal therapies (CRYSVITA for hypophosphatemic rickets)
First Approval: Australia, May 2023; European Union, November 2025; United States approval status confirmed but specific date not disclosed
Patent Status: Not yet disclosed
Also known as: HCH
Prevalence: Point prevalence: 1-9 / 100 000 (Worldwide) — source: Orphanet, validated.
Hypochondroplasia is characterized by disproportionate short stature, mild lumbar lordosis and limited extension of the elbow joints.
ClinicalTrials.gov lists 11 registered studies for Hypochondroplasia (AACT aggregate).
Phase breakdown: NA (5), PHASE2 (3), PHASE3 (2), PHASE2/PHASE3 (1)
Common investigational therapies:
Disease data sourced from MONDO Disease Ontology (MONDO:0007793), Orphanet — hypochondroplasia, NCT01111019, NCT01541306, NCT05328050, NCT06212947, NCT06410976, AACT (ClinicalTrials.gov aggregate), ClinicalTrials.gov, Open Targets Platform (CC BY 4.0).
Australia TGA Approval
Voxzogo approved in Australia with PBS codes 13270K, 13274P, 13275Q.
European Union EMA Approval
Voxzogo approved by the European Medicines Agency (EMEA/H/C/005475).
United States FDA Approval
Voxzogo approved in the United States under NDA 214938; specific approval date not disclosed.
Phase 3 Efficacy and Safety Study Active
Randomized, double-blind, placebo-controlled, multicenter study evaluating vosoritide in children with hypochondroplasia (NCT 2024-513129-22-00).
The musculo-skeletal therapeutic landscape includes several approved agents, though few are specifically indicated for hypochondroplasia. Bisphosphonate-based therapies (Ibandronic Acid Sandoz by Teva, Alendronic Acid/Colecalciferol combinations) represent a large class of bone-targeting agents approved for osteoporosis and related conditions. Monoclonal antibody approaches include Denosumab (VYSRIBLI by Intas, formerly Amgen) and Romosozumab (EVENITY by Amgen), which target bone remodeling pathways. Bone morphogenetic protein therapies (INDUCTOS) and other skeletal agents (OSIGRAFT, OSSEOR) address specific bone regeneration and mineralization needs. CRYSVITA (Kyowa Kirin) targets hypophosphatemic rickets, a related rare skeletal disorder. Voxzogo's differentiation lies in its specific indication for hypochondroplasia and its approval status across multiple major markets. Most competing agents are not indicated for hypochondroplasia specifically, suggesting limited direct competition in this rare disease niche. The competitive set reflects the broader musculo-skeletal therapeutic market rather than a focused hypochondroplasia treatment landscape, indicating Voxzogo may occupy a relatively unique position in this rare indication.
| Therapy | Company | Mechanism | Status |
|---|---|---|---|
| IBANDRONIC ACID SANDOZ | Teva Pharma GmbH | — | approved |
| CORORA | Amgen | — | approved |
| ACLASTA | Apotex Pty Ltd | — | approved |
| CRYSVITA | KYOWA KIRIN AUSTRALIA PTY LTD | — | approved |
| OSIGRAFT | — | — | approved |
| EVENITY | Amgen | — | approved |
| OSSEOR | — | — | approved |
| ALENDRONIC ACID / COLECALCIFEROL MYLAN | — | — | approved |
| VYSRIBLI (PREVIOUSLY DENOSUMAB INTAS) | — | — | approved |
| VANTAVO (PREVIOUSLY ALENDRONATE SODIUM AND COLECALCIFEROL, MSD) | — | — | approved |
| INDUCTOS | — | — | approved |
| Voxzogo 0.4 mg powder and solvent for solution for injection, Voxzogo 0.56 mg powder and solvent for solution for injection, Voxzogo 1.2 mg powder and solvent for solution for injection | BioMarin Pharmaceutical Australia Pty Ltd | small_molecule | phase_3 |
| VOSORITIDE | — | Atrial natriuretic peptide receptor B binding agent | Phase 3 |
| SOMATROPIN | — | Growth hormone receptor agonist | Phase 2 |
Additional associated therapies sourced from Open Targets Platform (CC0), linked to NovaPharmaNews drug profiles where matched.
Australia (TGA): Voxzogo approved May 1, 2023. PBS codes: 13270K, 13274P, 13275Q. Sponsor: BioMarin Pharmaceutical Australia Pty Ltd.
European Union (EMA): Voxzogo approved November 17, 2025. Marketing Authorization Holder: BioMarin International Limited. EMA Product Number: EMEA/H/C/005475.
United States (FDA): Voxzogo approved. Application Number: NDA 214938. Sponsor: BIOMARIN PHARM. Specific approval date not yet disclosed.
Japan (PMDA): Regulatory status not yet disclosed.
China (NMPA): Regulatory status not yet disclosed.
Patent Status: Not yet disclosed in available regulatory documentation.
Loss of Exclusivity: Expected loss of exclusivity date not yet disclosed.
Voxzogo (vosoritide) is used to treat hypochondroplasia, a rare genetic skeletal dysplasia characterized by short stature and disproportionate limb growth. It is administered as a subcutaneous injection to children with this condition.
Yes, Voxzogo is approved in Australia (May 2023), the European Union (November 2025), and the United States. Regulatory status in Japan and China has not yet been disclosed.
Voxzogo is developed and manufactured by BioMarin Pharmaceutical Australia Pty Ltd (sponsor in Australia) and BioMarin International Limited (marketing authorization holder in the EU).
The specific mechanism of action of vosoritide has not been disclosed in available regulatory or clinical documentation.
Voxzogo is administered as a subcutaneous injection. It is supplied as a powder and solvent for solution for injection, available in 0.56 mg and 1.2 mg formulations.
Hypochondroplasia is a rare genetic skeletal dysplasia that results in growth deficiency and skeletal abnormalities, causing short stature and disproportionate limb growth. It is a genetic condition with limited treatment options.
A Phase 3, randomized, double-blind, placebo-controlled, multicenter study (NCT 2024-513129-22-00) is currently active, evaluating the efficacy and safety of vosoritide in children with hypochondroplasia. Specific trial results have not yet been disclosed.
Voxzogo is classified as a musculo-skeletal system therapeutic (ATC M05) and is a small-molecule drug.
Limited specific competitors for hypochondroplasia exist. The broader musculo-skeletal therapeutic landscape includes bisphosphonates, monoclonal antibodies (denosumab, romosozumab), and bone morphogenetic proteins, but most are not indicated for hypochondroplasia specifically.
Voxzogo is available as a powder and solvent for solution for injection in 0.56 mg and 1.2 mg strengths. In Australia, PBS codes 13270K, 13274P, and 13275Q are assigned to different formulations.
In Australia, Voxzogo is listed on the PBS (Pharmaceutical Benefits Scheme) with codes 13270K, 13274P, and 13275Q, indicating government reimbursement. Coverage in other markets has not been disclosed.
Voxzogo is approved in Australia, the EU, and the US. A Phase 3 clinical trial is currently active, suggesting ongoing clinical development and potential label expansion studies.
The patent status and exclusivity duration for Voxzogo have not been disclosed in available regulatory or clinical documentation.
Projected peak sales figures have not been disclosed. Commercial potential is influenced by the rare disease population size, pricing strategies in orphan indications, and potential label expansions.
No partner or licensing arrangements are disclosed in available documentation. BioMarin Pharmaceutical appears to be the sole developer and sponsor.
Voxzogo is indicated for children with hypochondroplasia. The specific age range and patient selection criteria are not fully disclosed in available documentation.
111-303 → Drug → Target → Indication → Company → Trials → Competitors
Regulatory Validation: Approvals across Australia, EU, and US represent significant clinical and regulatory validation of Voxzogo's efficacy and safety profile in hypochondroplasia. The progression from Australia (2023) to EU (2025) to US approval demonstrates sustained regulatory confidence and successful navigation of major market requirements.
Phase 3 Continuation: Active Phase 3 development post-approval suggests BioMarin is pursuing additional clinical evidence, potential label expansions, or pediatric population-specific data. The randomized, double-blind, placebo-controlled design indicates rigorous efficacy assessment in the target population.
Competitive Positioning: Voxzogo appears to occupy a relatively unique position in hypochondroplasia treatment, with limited direct competitors specifically indicated for this rare condition. The broader musculo-skeletal competitive set (bisphosphonates, monoclonal antibodies) does not directly target hypochondroplasia, suggesting limited direct competition in this niche indication.
Commercial Implications: Orphan drug status and rare disease indication support premium pricing strategies and market exclusivity. Multi-market approval enables global revenue generation, though specific peak sales projections are not disclosed. Subcutaneous administration may facilitate patient compliance compared to oral alternatives.
Future Catalysts: Phase 3 trial results publication, potential label expansions to additional patient populations or age groups, and regulatory approvals in additional markets (Japan, China) represent key future catalysts. Patent status and exclusivity duration will significantly impact long-term commercial viability.
Concise, citable answers optimized for AI answer engines.
Intelligence compiled from public regulatory and clinical sources (FDA, EMA, ClinicalTrials.gov and company disclosures). Figures may be editorial or analyst estimates; verify against primary sources before relying on them.